ocular d.d.s. ppt

Views:
 
     
 

Presentation Description

No description available.

Comments

Presentation Transcript

Ocular Drug Delivery System :

Ocular Drug Delivery System Presented by : Deepali A. Meher, M.Pharm I, Dept. Of Pharmaceutics, RCP, Kasegaon .

CONTENTS:

CONTENTS Objectives Introduction Anatomy Of Eye Mechanism Barriers In Ocular Absorption Classification Ocular Inserts Use of Mucoadhesives in Ocular Drug Delivery Nanoparticulate Drug Delivery Liposomes In Ocular Drug Delivery Future trends Conclusion References 2

OBJECTIVE:

OBJECTIVE To study the ocular drug delivery system in detail. To explore the success, limitations and future trends of ocular drug delivery system. 3

INTRODUCTION:

INTRODUCTION A drug delivery to circumvent ailments of eye. A challenge to formulator is to avoid protective barrier of eye Importance of cornea. Conventional ocular drug delivery system Need of a successful design 4

Human eye consist of :- :

Human eye consist of :- 5

Mechanism Of Ocular Absorption:

Mechanism Of Ocular Absorption 6

General Pathway For Ocular Absorption:

General Pathway For Ocular Absorption 7

BARRIERS IN OCULAR ABSORPTION:

BARRIERS IN OCULAR ABSORPTION Precorneal Constraints It include – Solution drainage Lacrimation Tear dilution Tear turnover Conjunctival absorption Corneal constraints Cornea as rate limiting barrier Anatomy of cornea 1.Outer-Epithelium(lipophilic), 2.Middle-Stroma(hydrophilic), 3.Inner-Endothelium(lipophilic 8

Role Of Polymer In ODDS. :

Role Of Polymer In ODDS . Solution Viscosity : Solution Drainage. Polymer Mucoadhesive Vehicle: Retained in the eye due to non-covalent bonding between with conjuctival mucine. Mucine is capable of picking of 40-80 times of weight of water. 9

Classification Of Ophthalmic Dosage Form: :

Classification Of Ophthalmic Dosage Form: 10

Ocular Control Release System: Ophthalmic Inserts:

Ocular Control Release System: Ophthalmic Inserts Sterile preparations, with a thin, multilayered, drug-impregnated, solid or semisolid consistency devices placed into cul-de-sac or conjunctival sac. Advantages Increasing contact time and thus improving bioavailability. Providing a prolong drug release and thus a better efficacy. Reduction of systemic side effects and thus reduced adverse effects. Reduction of the number of administrations and thus better patient compliance. 11

Ocular Control Release System: Ophthalmic Inserts :

Ocular Control Release System: Ophthalmic Inserts - Solid or Semisolid in nature, - Placed in lower Fornix - Composed of Polymeric vehicle containing drug. Desired Criteria For Control Release Ocular Inserts. 12

Slide 13:

13

Types Of Ocular Control Release System:

Types Of Ocular Control Release System 14

A) Non-Erodible ::

A) Non-Erodible : 1.Ocusert: Developed by Alza Corporation, Oval flexible ocular insert, Release Rate: 20-40mg/hr for 7day Consist of- Annular ring : Impregnated with Ti0 2 : For Visibility Part Material Drug Reservoir Pilocarpine Carrier material Alginic acid Rate controller Ethylene vinyl acetate copolymer Energy Source Conc. Of Pilocarpine Delivery Portal Copolymer membrane 15

2) Contact Lens ::

2) Contact Lens : Presoaked Hydrophilic lens. Drug Release : within 1 st 30 Min . Alternate approach : incorporate drug either as sol n or suspension of solid monomer mixture. Release rate is up to : 180 hr . 3) Diffusional Inserts : Central reservoir of drug enclosed in Semi permeable or micro porous membrane for diffusion of drug. Diffusion is controlled by Lacrimal Fluid penetrating through it. It prevents continues decrease in release rate due to barrier. Release follows : Zero Order Kinetics . 16

B) Erodible Inserts:

B) Erodible Inserts 1.Lacrisert: Sterile, Rod Shaped device. Composition: HPC without preservative. Weight:5mg, Dimension:Diameter:12.5mm, Length:3.5mm Use:-Dry eye treatment, Keratitis Sicca. 2.SODI: Soluble Ocular Drug Insert. Small water soluble developed for Cosmonauts who could not use their eye drop in liquid condition. Composition : Acryl amide, N-vinylpyrolidone, Ethylacrylate. Weight 15-16 mg. In 10-15 sec Softens; In 10-15 min. turns in Viscous Liquids; After 30-60min. Becomes Polymeric Solution. 17

Advantages of SODI : :

Advantages of SODI : Single SODI application :replaces 4-12 eye drops Instillation, or 3-6 application of Ointments. Once a day treatment of Glaucoma & Trachoma. 3)Minidisc/Ocular therapeutic system: It is made up of counter disc with Convex front & Concave back surface in contact with eye ball. 4-5mm in diameter. Composition : Silicon based pre polymer. Hydrophilic or Hydrophobic. Drug release from OCT for170 hr. 18

C) Nanoparticle::

C) Nanoparticle: 19

Advantages of nanoparticles :

Advantages of nanoparticles Sustained drug release and prolonged therapeutic activity Site-specific targeting Higher cellular permeability Protect the drug from chemical or enzymatic hydrolysis Efficient in crossing membrane barriers -blood retinal barrier Act as an inert carrier for ophthalmic drugs 20

D) Liposome:

D) Liposome 21

USE OF MUCOADHESIVES IN OCULAR DRUG DELIVERY:

USE OF MUCOADHESIVES IN OCULAR DRUG DELIVERY Mucoadhesives contain the dosage form which remains adhered to cornea until the polymer is degraded or mucus replaces itself. Types- 1. Naturally Occurring Mucoadhesives- Lectins, Fibronectins 2. Synthetic Mucoadhesives-PVA,Carbopol, carboxy methyl cellulose, cross-linked polyacrylic acid Drugs incarporated in to this are pilocarpine, lidocaine, benzocaine and prednisolone acetate. 22

Advances in ocular drug delivery:

Advances in ocular drug delivery 1. Ophthalmic gel for pilocarpine Poloxamer 407 (low viscosity, optical clarity, mucomimetic property) 2. Ophthalmic prodrug Dipivalyl epinephrine (Dipivefrin) Lipophilic  increase in corneal absorption Esterase within cornea and aqueous humor 3. Continuous delivery system based upon the osmotic property Thin flat layer, contoured three-dimensional unit Conform to the space of the upper cul-de-sac Delivery of diethyl carbamazine in ocular onchocerciasis 23

4.Gel delivery system:

4.Gel delivery system Biodegradable polyisobutyl-cyano acrylate (PIBCA) colloidal particulate system of pilocarpine to incorporate it into a Pluronic F127 (PF 127)-based gel delivery system. 5)Mucoadhesive Polymer. mucoadhesive polymer, the tamarind seed polysaccharide, as a delivery system for the ocular administration of hydrophilic and hydrophobic antibiotics. 24

Future trends:

Future trends The sustained and controlled release technologies are being proposed and the possible benefits of using liposomes, nanoparticles and inserts will be at store in future. Targeted drug delivery with modifications of conventional, advanced and novel ocular drug deliveries has potential as future drug delivery for eye. It is possible to the give effective ocular drug delivery to any part of the eye. 25

Conclusion:

Conclusion Very few advanced ocular drug delivery systems have been commercialized. The performance of these new products, however, is still far from being perfect. Major improvements are required in each of the technologies discussed in this study. More clinical studies are necessary to provide further information and insights into these advanced ocular drug delivery systems . 26

Reference::

Reference: N.K.Jain, Advances in Controlled & Novel Drug Delivery, CBS Publication, & distributor, New Delhi, pg No.219-223. Remington & Gennaro ; The Science & Practice Of Pharmacy. Mack Publication Company. Easton, Pennsylvania. Pg. No. 1563-1567. Web Sites: www.vision-care-guide.com www.google/images/eye/anatomy& physiology 27

Thank You....! :

Thank You....! The eyes are the mirror of the soul… Take care of your eyes with gentleness . 28

authorStream Live Help